Little Capricor hits the brakes on a stem cell trial for Duchenne MD following an allergic reaction
The penny stock player Capricor Therapeutics $CAPR has stumbled into another pitfall.
The biotech noted that it has voluntarily halted a clinical trial of a stem cell therapy they had hoped would tamp down on the damaging inflammation associated with Duchenne muscular dystrophy. The halt was called following a “severe allergic reaction” that occurred during infusion, according to a filing with the SEC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.